ENGN vs GOSS: fair value comparison
enGene Holdings Inc. and Gossamer Bio, Inc. · Updated 2026-10-19
ENGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. GOSS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ENGN currently ranks higher by quality score.
| ENGN | GOSS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $1.67 | $8.77 |
| 12-month range | $1.44–$12.17 | $8.77–$303.20 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #238 of 301 Healthcare | #240 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Stable |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ENGN fair value analysis · GOSS fair value analysis